NMOSD

A 5-year retrospective analysis offered insights into disease characteristics, treatment responses, and clinical outcomes of neuromyelitis optica spectrum disorder as well as myelin oligodendrocyte glycoprotein antibody-associated disease.

A significant number of pregnancies in NMOSD patients experienced relapses postpartum, with 50% of pregnancies showing complications for both mother and fetus.

A large registry-based study analyzed treatment patterns and attack risks in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease.

A unique case highlighted the complex interplay between NMOSD and other autoimmune diseases, demonstrating the challenges in diagnosing and managing the condition.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on neuromyelitis optica spectrum disorder.

A 51-year-old patient with neuromyelitis optica spectrum disorder and hemorrhagic longitudinally extensive transverse myelitis presented a challenging case.

These findings underscore the potential of advanced imaging technologies to detect subtle gray matter differences, aiding in the accurate differentiation between MS and NMOSD.

A new study suggests particulate matter exposure exacerbated the severity of multiple sclerosis and neuromyelitis optica spectrum disorder, with significant clinical and radiological impacts.

Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune CNS condition with distinct subtypes—AQP4-IgG positive, MOGAD, and double-negative—each requiring tailored diagnostic and treatment approaches.

Patients who started therapy immediately after the initial attack had a relapse risk of just 11% at 2 years and 20% at 6 and 8 years, compared to much higher rates (41% at 2 years, 56% at 8 years) in those who delayed therapy until a second attack.

Ultimately, the biomarkers' temporal patterns may help differentiate attacks from remission, with sGFAP being particularly useful in distinguishing genuine attacks from pseudoattacks.

A recent multicenter study showed that dried blood spot testing for neuromyelitis optica spectrum disorder provided high accuracy and practicality in resource-limited settings.

A new study revealed stark racial and socioeconomic disparities in pediatric neuromyelitis optica spectrum disorder outcomes, underscoring the need for targeted interventions.

In a longitudinal study lasting 2 years, impaired test performance in semantic fluency and congruent speed were observed in patients with MOGAD relative to healthy controls.

The phase 1 study, which is currently recruiting, includes a 4-week screening period, a 52-week treatment period, and a 4-year long-term extension to continue to test the effects of HG202.

HNSA-5487 exhibited lower pre-treatment anti-drug antibody levels and reduced ADA responses compared to imlifidase, indicating a favorable immunogenicity profile and strong potential for redosing, with no serious adverse events observed.

The pair of neurologists provided clinical insight on a number of lingering non-treatment unmet needs for patients with MOGAD, including improved care for pediatric patients and underreported complications like sleep disturbances and genitourinary issues in adults. [WATCH TIME: 5 minutes]

In this discussion, the pair of neurologists explore the latest drug development and ongoing clinical trials for MOGAD, a rare neuroimmune disorder. [WATCH TIME: 4 minutes]

In this segment, Bennett and Greenberg explore the diagnosis, acute treatment, and long-term management of MOGAD, highlighting current therapies and ongoing research. [WATCH TIME: 8 minutes]

In this episode, Greenberg and Bennett provide some perspective on the fluidity of MOGAD diagnosis and how it could potentially change over time as more is understood about neuroimmune disorders. [WATCH TIME: 5 minutes]

In this segment, the duo of neurologists provided a number of informative considerations treating clinicians should take when diagnosing MOGAD, emphasizing careful testing and interpretation of data in this complex process. [WATCH TIME: 4 minutes]

For the majority of patients who were either aquaporin-4-antibody seropositive or seronegative, rituximab was the first disease-modifying therapy administered for neuromyelitis optica spectrum disorder.

The analysis revealed a significant link between the proportion of AQP4 antibody-positive cases and a higher female-to-male sex ratio in NMOSD.

Patients with myelin oligodendrocyte glycoprotein IgG-associated disease with severer attacks had higher C5b-9 levels than those with milder attacks.

Research indicated that up to 46% of patients diagnosed with presumed autoimmune limbic encephalitis tested negative for all currently identified central nervous system antigens.

Recent findings showed that treatment with satralizumab was likely associated with a reduction in the concomitant use of immunosuppressive therapies in neuromyelitis optica spectrum disorder.

The study highlights a dramatic decrease in income for patients following disease onset and a significantly higher proportion of them requiring social welfare jobs or disability pensions.

Most relapses occurred before patients resumed immunotherapy after giving birth, suggesting that continued immunosuppression during pregnancy might help prevent attacks.

The study found a 98% agreement between treating physicians’ initial diagnoses and the new MOGAD criteria.

Investigators found that in melanomas in particular, interleukin-6 blockade seems to be effective in the management of immune-related adverse events from immune checkpoint inhibitors.